ATOS vs. EYEG, JAGX, TTPH, GHRS, AVBP, PHAT, LYEL, SLN, LRMR, and ABUS
Should you be buying Atossa Therapeutics stock or one of its competitors? The main competitors of Atossa Therapeutics include AB Corporate Bond ETF (EYEG), Jaguar Health (JAGX), Tetraphase Pharmaceuticals (TTPH), GH Research (GHRS), ArriVent BioPharma (AVBP), Phathom Pharmaceuticals (PHAT), Lyell Immunopharma (LYEL), Silence Therapeutics (SLN), Larimar Therapeutics (LRMR), and Arbutus Biopharma (ABUS). These companies are all part of the "medical" sector.
AB Corporate Bond ETF (NASDAQ:EYEG) and Atossa Therapeutics (NASDAQ:ATOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.
AB Corporate Bond ETF has higher revenue and earnings than Atossa Therapeutics. AB Corporate Bond ETF is trading at a lower price-to-earnings ratio than Atossa Therapeutics, indicating that it is currently the more affordable of the two stocks.
AB Corporate Bond ETF has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Atossa Therapeutics has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500.
64.2% of AB Corporate Bond ETF shares are owned by institutional investors. Comparatively, 12.7% of Atossa Therapeutics shares are owned by institutional investors. 58.2% of AB Corporate Bond ETF shares are owned by insiders. Comparatively, 7.6% of Atossa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
AB Corporate Bond ETF's return on equity of -32.79% beat Atossa Therapeutics' return on equity.
Atossa Therapeutics has a consensus price target of $5.75, indicating a potential upside of 360.00%. Given AB Corporate Bond ETF's stronger consensus rating and higher possible upside, analysts clearly believe Atossa Therapeutics is more favorable than AB Corporate Bond ETF.
In the previous week, Atossa Therapeutics had 5 more articles in the media than AB Corporate Bond ETF. MarketBeat recorded 6 mentions for Atossa Therapeutics and 1 mentions for AB Corporate Bond ETF. AB Corporate Bond ETF's average media sentiment score of 0.72 beat Atossa Therapeutics' score of 0.00 indicating that Atossa Therapeutics is being referred to more favorably in the news media.
AB Corporate Bond ETF received 208 more outperform votes than Atossa Therapeutics when rated by MarketBeat users. Likewise, 71.04% of users gave AB Corporate Bond ETF an outperform vote while only 65.07% of users gave Atossa Therapeutics an outperform vote.
Summary
Atossa Therapeutics beats AB Corporate Bond ETF on 10 of the 16 factors compared between the two stocks.
Get Atossa Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atossa Therapeutics Competitors List
Related Companies and Tools
